Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation Marta Palomo,

Slides:

Advertisements

Similar presentations

Evidence of B Cell Immune Responses to Acute Lymphoblastic Leukemia in Murine Allogeneic Hematopoietic Stem Cell Transplantation Recipients Treated with.

Advertisements

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Serial Profile of Vitamins and Trace Elements during the Acute Phase of Allogeneic Stem Cell Transplantation Yasuhito Nannya, Akihito Shinohara, Motoshi.

Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation María.

Increased Plasma Indoleamine 2,3-Dioxygenase Activity and Interferon-γ Levels Correlate with the Severity of Acute Graft-versus-Host Disease after Allogeneic.

Relative Survival of Long-Term Hematopoietic Cell Transplant Recipients Approaches General Population Rates Ian Nivison-Smith, Judy M. Simpson, Anthony.

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Pharmacokinetics of Ganciclovir after Oral Valganciclovir versus Intravenous Ganciclovir in Allogeneic Stem Cell Transplant Patients with Graft-versus-Host.

Predictive Value of Circulating Angiopoietin-2 for Endothelial Damage–Related Complications in Allogeneic Hematopoietic Stem Cell Transplantation Norihiro.

The Release of Soluble Factors Contributing to Endothelial Activation and Damage after Hematopoietic Stem Cell Transplantation Is Not Limited to the Allogeneic.

Defibrotide Prevents the Activation of Macrovascular and Microvascular Endothelia Caused by Soluble Factors Released to Blood by Autologous Hematopoietic.

Allogeneic Stem Cell Transplantation in Myelofibrosis

Sympathectomy Protects Denervated Skin from Graft-Versus-Host Disease

Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients Bernard Lawrence Marini, Sung Won Choi, Craig Alan Byersdorfer, Simon.

Gastrointestinal Toxicity, Systemic Inflammation, and Liver Biochemistry in Allogeneic Hematopoietic Stem Cell Transplantation Karina Jordan, Peter Pontoppidan,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection.

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Betty T. Tran, Abigail Halperin, Jason W. Chien

Autologous Is Superior to Allogeneic Hematopoietic Cell Transplantation for Acute Promyelocytic Leukemia in Second Complete Remission Jennifer L. Holter.

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

Stem Cell Transplant for Children with Sickle Cell Anemia: Parent and Patient Interest Michael Roth, Julie Krystal, Deepa Manwani, Catherine Driscoll,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Anemia Associated with Impaired Erythropoietin Secretion after Allogeneic Stem Cell Transplantation: Incidence, Risk Factors, and Response to Treatment

Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma Jessica Rueff, Michael Medinger,

Late-Onset Colitis after Cord Blood Transplantation Is Consistent with Graft-Versus-Host Disease: Results of a Blinded Histopathological Review Filippo.

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Sequential Intensified Conditioning and Tapering of Prophylactic Immunosuppressants for Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell.

Graft-Versus-Host Disease Targets Granulosa Cell of Ovarian Follicle and Causes Infertility after Allogeneic Hematopoietic Stem Cell Transplantation

Epidemiology, Management, and Outcome of Invasive Fungal Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation in China: A Multicenter.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients Pooja Khandelwal, Sabine Mellor-Heineke, Najibah.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Protective Immunity Transferred by Infusion of Cytomegalovirus-Specific CD8+ T Cells within Donor Grafts: Its Associations with Cytomegalovirus Reactivation.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Acute Kidney Injury and the Risk of Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation Sarah J. Kizilbash, Clifford E. Kashtan,

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

What is quality in a transplant program?

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Biology of Blood and Marrow Transplantation

Unrelated Stem Cell Transplantation after a Reduced Intensity Conditioning Regimen Containing High-Dose Thymoglobulin Leads to Controllable Graft-versus-Host.

John E. Levine, Sophie Paczesny, Stefanie Sarantopoulos

Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-

Therapeutic Immunosuppression Concentrations on Day 0 and the Development of Acute Graft Versus Host Disease (GVHD) in Hematopoietic Stem Cell Transplantation.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Reticulocyte Maturation Parameters Are Reliable Early Predictors of Hematopoietic Engraftment after Allogeneic Stem Cell Transplantation J.R. Molina,

A Meta-analysis of Patients Receiving Allogeneic or Autologous Hematopoietic Stem Cell Transplant in Mycosis Fungoides and Sézary Syndrome Peggy A. Wu,

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Distinct Deleterious Effects of Cyclosporine and Tacrolimus and Combined Tacrolimus– Sirolimus on Endothelial Cells: Protective Effect of Defibrotide

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Yuri Fedoriw, T. Danielle Samulski, Allison M. Deal, Cherie H

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Altered Functional Status of the Hypothalamic Dopaminergic Tone in Patients with Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem.

Lawrence Chang, David Frame, Thomas Braun, Erin Gatza, David A

Mary Eapen Biology of Blood and Marrow Transplantation

Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma: The Stanford Experience Andy I. Chen, Alex McMillan,

Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma Luciano J. Costa, Jia-Xing Huang, Parameswaran.

Presentation transcript:

Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation Marta Palomo, Maribel Diaz-Ricart, Carla Carbo, Montserrat Rovira, Francesc Fernandez-Aviles, Carmen Martine, Gabriela Ghita, Ginés Escolar, Enric Carreras Biology of Blood and Marrow Transplantation Volume 16, Issue 7, Pages 985-993 (July 2010) DOI: 10.1016/j.bbmt.2010.02.008 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Changes in plasmatic levels of vWF and ADAMTS-13 activity. Graphs represent changes in VWF (●) and ADAMTS-13 activity (○) levels in plasma samples from recipients of autologous HSCT with BEAM and MLF conditioning treatments, and of allogeneic HSCT with Cy/TBI and Flu/MLF treatments, as indicated. Levels were determined at the different time points of the study: before starting conditioning regimen (Pre), immediately before the infusion of the hematopoietic stem cells (day 0), and days 7, 14, and 21 after the HSCT. Data are expressed as ratios with respect to the Pre value and correspond to mean ± SEM (∗P < .05; n = 6, 5, 5, and 8 for the BEAM, MLF, Cy/TBI, and Flu/MLF, respectively). Biology of Blood and Marrow Transplantation 2010 16, 985-993DOI: (10.1016/j.bbmt.2010.02.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Changes in the levels of sVCAM-1 and sICAM-1 in patients without TRC from the autologous and allogeneic groups. Graphs represent changes in soluble VCAM-1 and ICAM-1 levels in plasma from recipients of autologous HSCT with BEAM (●) and MLF (○) conditioning treatments, and of allogeneic HSCT with Cy/TBI (▴) and Flu/MLF (Δ) treatments. Levels were determined at the different time points of the study: before starting conditioning regimen (Pre), immediately before the infusion of the hematopoietic stem cells (day 0), and days 7, 14, and 21 after the HSCT. Data are expressed as ratios with respect to the Pre value and correspond to mean ± SEM (∗P < 0.05; n = 6, 5, 5, and 8 for the BEAM, MLF, Cy/TBI, and Flu/MLF, respectively). Biology of Blood and Marrow Transplantation 2010 16, 985-993DOI: (10.1016/j.bbmt.2010.02.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Levels of plasmatic soluble TNF receptor I in patients without TRC. Graphs representing changes in soluble TNFRI levels in plasma from recipients of autologous HSCT with BEAM (●) and MLF (○) conditioning treatments, and of allogeneic HSCT with Cy/TBI (▴) and Flu/MLF (▵) treatments. Levels were determined at the different time points of the study: before starting conditioning regimen (Pre), immediately before the infusion of the hematopoietic stem cells (day 0), and days 7, 14, and 21 after the HSCT. Data are expressed as ratios with respect to the Pre value and correspond to mean ± SEM (∗P < .05; n = 6, 5, 5, and 8 for the BEAM, MLF, Cy/TBI and Flu/MLF, respectively). Biology of Blood and Marrow Transplantation 2010 16, 985-993DOI: (10.1016/j.bbmt.2010.02.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Kinetics of VWF in patients with TRC versus those without complications. Graphs show VWF levels in recipients of autologous HSCT (a) and allogeneic HSCT (b and c) with (•) and without (o) transplant related complications. ES = engraftment syndrome (n =11); GVHD = graft-versus-host disease (n = 7); VOD = venooclusive disease (n = 2). Data are expressed as absolute values in % (mean ± SEM) (∗P < .05; for days 7, 14, and 21 versus day Pre). Biology of Blood and Marrow Transplantation 2010 16, 985-993DOI: (10.1016/j.bbmt.2010.02.008) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions